Cargando…
Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia
BACKGROUND: Hyperkalemia can be harmful, but the effect of correcting hyperkalemia is sparsely studied. We used nationwide data to examine hyperkalemia follow‐up in patients with hypertension. METHODS AND RESULTS: We identified 7620 patients with hypertension, who had the first plasma potassium meas...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955366/ https://www.ncbi.nlm.nih.gov/pubmed/33317370 http://dx.doi.org/10.1161/JAHA.120.017087 |
_version_ | 1783664235782340608 |
---|---|
author | Krogager, Maria Lukács Søgaard, Peter Torp‐Pedersen, Christian Bøggild, Henrik Gislason, Gunnar Kragholm, Kristian |
author_facet | Krogager, Maria Lukács Søgaard, Peter Torp‐Pedersen, Christian Bøggild, Henrik Gislason, Gunnar Kragholm, Kristian |
author_sort | Krogager, Maria Lukács |
collection | PubMed |
description | BACKGROUND: Hyperkalemia can be harmful, but the effect of correcting hyperkalemia is sparsely studied. We used nationwide data to examine hyperkalemia follow‐up in patients with hypertension. METHODS AND RESULTS: We identified 7620 patients with hypertension, who had the first plasma potassium measurement ≥4.7 mmol/L (hyperkalemia) within 100 days of combination antihypertensive therapy initiation. A second potassium was measured 6 to 100 days after the episode of hyperkalemia. All‐cause mortality within 90 days of the second potassium measurement was assessed using Cox regression. Mortality was examined for 8 predefined potassium intervals derived from the second measurement: 2.2 to 2.9 mmol/L (n=37), 3.0 to 3.4 mmol/L (n=184), 3.5 to 3.7 mmol/L (n=325), 3.8 to 4.0 mmol/L (n=791), 4.1 to 4.6 mmol/L (n=3533, reference), 4.7 to 5.0 mmol/L (n=1786), 5.1 to 5.5 mmol/L (n=720), and 5.6 to 7.8 mmol/L (n=244). Ninety‐day mortality in the 8 strata was 37.8%, 21.2%, 14.5%, 9.6%, 6.3%, 6.2%, 10.0%, and 16.4%, respectively. The multivariable analysis showed that patients with concentrations >5.5 mmol/L after an episode of hyperkalemia had increased mortality risk compared with the reference (hazard ratio [HR], 2.27; 95% CI, 1.60–3.20; P<0.001). Potassium intervals 3.5 to 3.7 mmol/L and 3.8 to 4.0 mmol/L were also associated with increased risk of death (HR, 1.71; 95% CI, 1.23–2.37; P<0.001; HR, 1.36; 95% CI, 1.04–1.76; P<0.001, respectively) compared with the reference group. We observed a trend toward increased risk of death within the interval 5.1 to 5.5 mmol/L (HR, 1.29; 95% CI, 0.98–1.69). Potassium concentrations <4.1 mmol/L and >5.0 mmol/L were associated with increased risk of cardiovascular death. CONCLUSIONS: Overcorrection of hyperkalemia to levels <4.1 mmol/L was frequent and associated with increased all‐cause and cardiovascular mortality. Potassium concentrations >5.5 mmol/L were also associated with an increased all‐cause and cardiovascular mortality. |
format | Online Article Text |
id | pubmed-7955366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79553662021-03-17 Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia Krogager, Maria Lukács Søgaard, Peter Torp‐Pedersen, Christian Bøggild, Henrik Gislason, Gunnar Kragholm, Kristian J Am Heart Assoc Original Research BACKGROUND: Hyperkalemia can be harmful, but the effect of correcting hyperkalemia is sparsely studied. We used nationwide data to examine hyperkalemia follow‐up in patients with hypertension. METHODS AND RESULTS: We identified 7620 patients with hypertension, who had the first plasma potassium measurement ≥4.7 mmol/L (hyperkalemia) within 100 days of combination antihypertensive therapy initiation. A second potassium was measured 6 to 100 days after the episode of hyperkalemia. All‐cause mortality within 90 days of the second potassium measurement was assessed using Cox regression. Mortality was examined for 8 predefined potassium intervals derived from the second measurement: 2.2 to 2.9 mmol/L (n=37), 3.0 to 3.4 mmol/L (n=184), 3.5 to 3.7 mmol/L (n=325), 3.8 to 4.0 mmol/L (n=791), 4.1 to 4.6 mmol/L (n=3533, reference), 4.7 to 5.0 mmol/L (n=1786), 5.1 to 5.5 mmol/L (n=720), and 5.6 to 7.8 mmol/L (n=244). Ninety‐day mortality in the 8 strata was 37.8%, 21.2%, 14.5%, 9.6%, 6.3%, 6.2%, 10.0%, and 16.4%, respectively. The multivariable analysis showed that patients with concentrations >5.5 mmol/L after an episode of hyperkalemia had increased mortality risk compared with the reference (hazard ratio [HR], 2.27; 95% CI, 1.60–3.20; P<0.001). Potassium intervals 3.5 to 3.7 mmol/L and 3.8 to 4.0 mmol/L were also associated with increased risk of death (HR, 1.71; 95% CI, 1.23–2.37; P<0.001; HR, 1.36; 95% CI, 1.04–1.76; P<0.001, respectively) compared with the reference group. We observed a trend toward increased risk of death within the interval 5.1 to 5.5 mmol/L (HR, 1.29; 95% CI, 0.98–1.69). Potassium concentrations <4.1 mmol/L and >5.0 mmol/L were associated with increased risk of cardiovascular death. CONCLUSIONS: Overcorrection of hyperkalemia to levels <4.1 mmol/L was frequent and associated with increased all‐cause and cardiovascular mortality. Potassium concentrations >5.5 mmol/L were also associated with an increased all‐cause and cardiovascular mortality. John Wiley and Sons Inc. 2020-12-02 /pmc/articles/PMC7955366/ /pubmed/33317370 http://dx.doi.org/10.1161/JAHA.120.017087 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Krogager, Maria Lukács Søgaard, Peter Torp‐Pedersen, Christian Bøggild, Henrik Gislason, Gunnar Kragholm, Kristian Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia |
title | Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia |
title_full | Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia |
title_fullStr | Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia |
title_full_unstemmed | Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia |
title_short | Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia |
title_sort | impact of plasma potassium normalization on short‐term mortality in patients with hypertension and hyperkalemia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955366/ https://www.ncbi.nlm.nih.gov/pubmed/33317370 http://dx.doi.org/10.1161/JAHA.120.017087 |
work_keys_str_mv | AT krogagermarialukacs impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia AT søgaardpeter impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia AT torppedersenchristian impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia AT bøggildhenrik impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia AT gislasongunnar impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia AT kragholmkristian impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia |